Successful treatment of cranial dystonia using a Zolpidem+Melatonin combination: A video case-series

Narendrakumar H Barad,Eoin Mulroy,Narendrakumar H. Barad
DOI: https://doi.org/10.1016/j.jns.2024.122986
IF: 4.4
2024-04-06
Journal of the Neurological Sciences
Abstract:Absrtact Introduction Cranial dystonias (CrD) are challenging to treat. Oral pharmacotherapy is often sub-optimal, while delicate anatomy and limited availability of skilled botulinum toxin injectors makes this approach risky, and often difficult to access; neurosurgical options e.g. deep brain stimulation, are high-risk in the elderly populations most affected. We observed significant improvement in CrD in 2 patients prescribed Zolpidem/Melatonin combination treatment for insomnia, and therefore trialled this treatment in a further 4 patients with CrD. Methods Six patients were treated with Zolpidem+Melatonin. Pre- and post-treatment videotaped clinical examinations were blindly rated by an independent assessor (EM) and scored using the 'Facial and Oral Movements' section of the abnormal involuntary movements scale (AIMS), as well as the Jankovic rating scale for blepharospasm. Results Dystonic features, as measured by the abnormal involuntary movements scale (AIMS) improved by an average of 75% after treatment (6.5±3.1 before treatment to 1.7 +/− 0.8 after treatment). Improvements were also observed in blepharospasm severity scores, and in cervical dystonic features. Conclusion Zolpidem+Melatonin combination treatment represents a safe and effective treatment for CrD. Low cost and wide availability makes it an attractive option, particularly in resource-constrained healthcare settings, or in patients who have failed, or lack access to alternatives.
neurosciences,clinical neurology
What problem does this paper attempt to address?